|Bid||59.240 x 3200|
|Ask||59.250 x 800|
|Day's Range||58.430 - 59.490|
|52 Week Range||52.830 - 66.410|
|PE Ratio (TTM)||68.03|
|Forward Dividend & Yield||1.92 (3.22%)|
|1y Target Est||N/A|
T hree patients infected with the Ebola virus slipped out of an isolation ward at a hospital in the Congolese city of Mbandaka, health officials said, as medics raced to stop the deadly disease from spreading in the busy river port. Two patients left the hospital on Monday night with the help of family members, then headed to a church, the World Health Organization's spokesman in Congo, Eugene Kabambi, told Reuters.
Merck & Co said on Wednesday its drug Keytruda helped patients with a certain type of lung cancer live longer and prevented the disease from spreading, helping to solidify its position in the lucrative cancer market. Keytruda, already approved for other types of cancer, is being studied in a late-stage trial as a first-line treatment, in combination with chemotherapy, for metastatic squamous non-small cell lung cancer (sNSCLC) patients. Merck said the combination therapy met its main trial goals when compared to patients who were on chemotherapy alone, according to an interim analysis.
LONDON (Reuters) - - In the life-and-death race to make the first effective vaccine against Ebola, one company - Merck (MRK.N) - seems bound to win. Immunisations with Merck's VSV EBOV experimental shot began in Congo this week - a big moment in a 40-year fight against a disease that until now could only be tackled by isolation and strict hygiene. Having this vaccine means the world is better placed now than it was in 2014-2016, when the haemorrhagic fever killed more than 11,300 people in history's worst Ebola outbreak in West Africa.
T hree patients infected with the deadly Ebola virus escaped from a hospital holding them in quarantine in the Congo city of Mbandaka, an aid group said, as medics raced to stop the disease spreading in the teeming river port. Two of the patients got out on Monday but were found dead a day later, said Henri Gray, the head of the Medecins Sans Frontieres (MSF) mission in the city. The report came as the World Health Organization warned that the fight to stop Democratic Republic of Congo's ninth confirmed outbreak of the hemorrhagic fever had reached a critical point.
The World Health Organization has started to vaccinate thousands of people considered at high risk of contacting the infectious and often-deadly disease Ebola in the Democratic Republic of Congo. The WHO said Monday it is working with NGOs and community leaders to administer an experimental vaccine that was studied in a trial in Guinea in 2015, but has not yet been used to contain a major outbreak. Most are in a remote town, but there are four confirmed cases in Mbandaka, the provincial capital which has a population of more than 1 million people.
T wo of three Ebola patients who escaped quarantine in the Congo river port city of Mbandaka have died, the head of medical charity Medecins Sans Frontieres' mission in the city said on Wednesday. The ...
Late last week, Johnson & Johnson (JNJ) announced that it was scrapping its mid-stage trial for the development of the treatment of Alzheimer’s disease, EARLY, which was in Phase 2b/3. The trial was testing the BACE inhibitor atabecestat. Johnson & Johnson is the latest in a series of companies, including Pfizer (PFE), Merck & Company (MRK), and Eli Lilly and Company (LLY), that have abandoned trials for their Alzheimer’s drug candidates.
Health officials in the Democratic Republic of Congo began administering an experimental Ebola vaccine, as the country battles to contain its ninth outbreak of the hemorrhagic fever. The first people to receive the vaccine on Monday were staff at a 20-bed Ebola treatment center set up by medical charity Doctors Without Borders in the northwestern city of Mbandaka, said Jessica Ilungu, a spokeswoman for Congo’s public-health ministry.
British finance minister Philip Hammond is looking for a new governor of the Bank of England to replace Mark Carney when he leaves the central bank next year. The position is one of the most powerful in Britain with responsibilities for steering interest rates for the world's fifth-biggest economy and overseeing the City of London's vast financial services industry. Following is a summary of how some of the BoE's governors of the last 50 years have faced up to the challenges of the job.
C ongo began administering an experimental Ebola vaccine to medical staff in the northwestern city of Mbandaka on Monday to tackle an outbreak of the virus believed to have killed 26 people since early April. The World Health Organization (WHO) hailed the vaccinations as a "paradigm shift" in how to fight the disease which killed more than 11,300 people in a West African epidemic between 2013 and 2016. The WHO is sending over 7,540 doses of the vaccine to the central African country, 540 of which have been earmarked for Mbandaka, a city of about 1.5 million where four Ebola cases have been confirmed.
A lot of large-cap familiar names are still called “blue-chip stock” when they are nothing of the kind. If you can’t rid the term “blue-chip stock” from your lexicon, then it should at least apply to a whole new stream of companies. “Blue-chip stock” used to refer to companies that were constantly growing earnings in the high single-digits or more in terms of percentage, had a fortress balance sheet and were constantly innovating.
In the first quarter, Roche Holding (RHHBY) reported revenues of ~13.6 billion Swiss francs compared to ~12.9 billion Swiss francs in the first quarter of 2017, which reflected ~5.0% growth on a YoY (year-over-year) basis.
Health workers in Democratic Republic of Congo will begin a vaccination campaign on Monday aimed at containing an outbreak of the deadly Ebola virus, a spokeswoman for the health ministry said on Sunday. ...
Eli Lilly (LLY) reported EPS of $1.34 and revenues of $5.7 billion in the first quarter. Both results surpassed Wall Street analysts’ estimates.
Johnson & Johnson ( JNJ) shares may drop by about 10% based on an analysis of the technical chart. Should shares of the stock fall an additional 10%, it would mean Johnson and Johnson would have dropped by nearly 25% from its intraday high of around $148 on January 22. The technical setup continues to be negative in the stock, and it appears shares could fall from roughly $124.25 to about $111.33, a drop of 10.4%.
The ability to sell new drugs hinges on approvals from government bodies such as the Food and Drug Administration (FDA). As a result, biotech companies, and to some degree, large drug companies, go into business ventures without the certainty of ever earning revenues, let alone profits. Biotech stocks often become some of the most difficult to evaluate.
During the first quarter, Gilead Sciences (GILD) entered into a scientific collaboration with Verily Life Sciences to identify and better understand the immunological basis of three common, serious inflammatory diseases—rheumatoid arthritis, inflammatory bowel disease, and lupus-related diseases—by making use of Verily’s Immunoscape platform.
Roche's (RHHBY) immuno-oncology drug, Tecentriq, in combination with Avastin and chemotherapies leads to significantly longer overall survival rates in treatment-naive NSCLC patients.
Novartis (NVS) is one of the leading pharmaceutical companies worldwide. AveXis (AVXS) is a US-based clinical-stage gene therapy company. On May 15, Novartis announced that it completed the acquisition of AveXis.
The Zacks Analyst Blog Highlights: Home Depot, Merck, Raytheon, Eaton and Sun Life Financial
Gilead Sciences (GILD) stock has corrected 9.6% since the start of 2018 to close at $66.99 on May 15. In comparison, Johnson & Johnson (JNJ), Pfizer (PFE), and Merck & Co. (MRK) have returned -9.5%, -2.1%, and 5.3%, respectively.
Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage trial released on Wednesday. The Phase III study involved 800 people with non-squamous non-small cell lung cancer (NSCLC) whose cancer had spread but who had not yet received chemotherapy.
The combination of Merck & Co's immunotherapy Keytruda and chemotherapy boosted response rates in patients with advanced hard-to-treat squamous cell lung cancer, the company said on Wednesday. An early look at results of a 204-patient trial showed an overall response rate of 58.4 percent for newly-diagnosed patients given Keytruda plus carboplatin and paclitaxel or Celgene Corp's Abraxane. The interim results will be discussed in greater detail next month at the annual meeting of the American Society of Clinical Oncology (ASCO), where data from several Keytruda trials and other therapies that help the immune system fight cancer will be presented.